Emerging Molecules
Before the obesity trials, tirzepatide had to win a diabetes phase 2
Frias and colleagues tested LY3298176, the dual GIP and GLP-1 agonist later named tirzepatide, against placebo and an active comparator in type 2 diabetes.
Tirzepatide did not appear first as a weight-loss brand. Frias and colleagues published a phase 2 trial in The Lancet of LY3298176 in people with type 2 diabetes, randomized against placebo and an active comparator. The point of that study was glucose, with weight as a closely watched companion endpoint. Dual agonism at GIP and GLP-1 was the mechanistic bet: that adding GIP receptor activity to a GLP-1 backbone would move clinical numbers beyond GLP-1 alone.
Why the early trial still matters
SURMOUNT-1 is easier to quote. The phase 2 diabetes trial is where the dose range and the tolerability story were sketched, including the gastrointestinal effects that have followed every drug in this class. Reading it keeps the later obesity percentages from looking like they came out of nowhere. It also shows the molecule’s path was a conventional one: code name, sponsor trial, journal, then brand. That path is the opposite of a research-chemical code invented for a storefront.
Emerging does not mean unregulated
This section of the journal is for molecules whose evidence is still moving. Tirzepatide has since moved into approved labels for diabetes and for chronic weight management. The phase 2 paper remains the right citation for the first controlled look, and the labels remain the right citation for what is actually approved.